Zeleciment Rostudirsen
X-Linked Disease
Dyne TherapeuticsPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the X-Linked Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ataluren PTC Therapeutics | Phase 3 | B |
Aoc 1044 Avidity Biosciences, Inc. | Phase 3 | B |
Deramiocel Capricor Inc. | Phase 3 | B |
Allogeneic Cardiosphere-Derived Cells Capricor Inc. | Phase 2 | B |
Spk-8016 Spark Therapeutics, Inc. | Phase 1/2 | CCC |
Delpacibart Zotadirsen | D |
Same molecule, other indications
Zeleciment Rostudirsen is also rated in:
neuromuscular disease caused by qualitative or quantitative defects of dystrophinDormant
B
Indicative ·
60 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →